Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
about
Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary diseaseNew clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analysesTiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions."Show me the money": a fair criticism of economic studies on inhaled bronchodilators for COPD.Comparing methods of data synthesis: re-estimating parameters of an existing probabilistic cost-effectiveness model.Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis.Markers of exacerbation severity in chronic obstructive pulmonary diseaseEvaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease.Utility estimation of hypothetical chronic obstructive pulmonary disease health states by the general population and health professionalsModelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain.Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.Present and future costs of COPD in Iceland and Norway: results from the BOLD studyCost effectiveness of collagen crosslinking for progressive keratoconus in the UK NHS.Improving clinical reality in chronic obstructive pulmonary disease economic modelling : development and validation of a micro-simulation approach.Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.Pharmacoeconomics in COPD: lessons for the futureA UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use.An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.Cost-effectiveness of combination therapy for chronic obstructive pulmonary diseaseCost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPDCost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.Obstructive lung disease models: what is valid?Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom.Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years.Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease.Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease.Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues.The role of value-of-information analysis in a health care research priority setting: a theoretical case study.Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.The effect of tiotropium bromide on health-related quality of life in chronic obstructive pulmonary disease.Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice.A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease.A mathematical approach for evaluating Markov models in continuous time without discrete-event simulation.Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK
P2860
Q24200476-D1531440-629C-4E8F-82D3-9777DA2639EAQ30419928-16D9B0C5-0F38-41D0-B141-8FABFAD390E4Q33693222-BE68CCBE-2B81-4B74-9E11-F3D632130036Q33693227-01F7B4C2-DBA9-4EA4-858B-93DD82B10D0BQ33766133-0ED72454-1813-4797-B628-8BE8B2C38795Q33794408-357C1E07-85C6-41FD-B66E-FA8DCB91A4E8Q34691221-0273DF6E-8CFA-4A2C-91C9-82960999F6EAQ35205369-49042B15-F1DA-4682-A740-23014F14F514Q35238199-3C1A540E-CE8E-4694-9870-1333D84468D4Q35878722-36633D24-5DD3-4E5E-97DE-2C0A59110736Q35885176-45E17AE7-C134-4CB7-AF63-EAA3C6DC64AAQ35906562-33212EF0-4814-4AC0-B9A7-2300C61861B6Q36281455-07C98431-11F0-4081-8384-2F61900F851EQ36579746-F95170EB-6CDD-409C-85E1-52AEEB589EEFQ36584673-76FACCD7-AB9A-4CC0-A0A2-DB71FB76DE12Q36859464-F97C0EB4-76CD-4A6A-A86F-525189F1CA5EQ36875110-4610F24F-D8B2-4132-AFAD-0F88DFF22C6CQ37150465-07CAD6E0-7DB7-450B-934E-3263232DFD43Q37192340-4FFA51E4-F16D-4CDE-ADA3-85F3423B0F47Q37261891-343652EF-1DA3-48DD-AAA2-2DE177213137Q37283438-F384DBC0-26FF-4E91-BE69-740BF0BDD357Q37437429-EBBD4F42-489E-4DC0-B44D-5D059DECF908Q37470650-82279D59-C243-40F7-81DC-0473039654E8Q37698624-46E5FED9-EB78-45EE-9C8B-B10B91478ACCQ37730578-C195080D-A574-4D9D-AD4D-62F58EB57A94Q37973132-588376BF-9C74-4268-8710-835C3F06CB0BQ37987211-CBE03A83-3994-4E7B-B57D-5F7CE0060A78Q37992679-66085D05-9EBB-4B2A-8BE0-275709806B2AQ39494022-E9481D86-346E-4F71-A1BC-D144EE3F783FQ39609265-88409D2E-C5BC-4C61-8722-EE496A60AD6CQ43042782-FAA0DDF6-B7EF-4FD0-AFBB-EA3596C8E494Q47138380-B01F3A4F-B14E-4753-8458-1E7306B1171FQ47380594-4D975B55-FABA-4C6D-AAD2-E7C851E4E6FDQ48953049-9AD5BB86-2D87-4FB6-9A2B-588C6F620BB5Q57161724-A6314284-F3DD-4B56-B107-75356DCFD02E
P2860
Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Probabilistic Markov model to ...... tients in different countries.
@en
Probabilistic Markov model to ...... tients in different countries.
@nl
type
label
Probabilistic Markov model to ...... tients in different countries.
@en
Probabilistic Markov model to ...... tients in different countries.
@nl
prefLabel
Probabilistic Markov model to ...... tients in different countries.
@en
Probabilistic Markov model to ...... tients in different countries.
@nl
P2093
P1433
P1476
Probabilistic Markov model to ...... atients in different countries
@en
P2093
Brigitta U Monz
J Mark FitzGerald
Jan B Oostenbrink
P356
10.1111/J.1524-4733.2005.03086.X
P577
2005-01-01T00:00:00Z